Kymeta Welcomes Industry Leaders to Board of Advisors
14.1.2025 17:00:00 CET | Business Wire | Press release
The world-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com) announced today the addition of two new members to the Board of Advisors, James Geurts and Elizabeth Kimber.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114298718/en/
(Graphic: Business Wire)
The Honorable James Geurts, known to most as Hondo, has over three decades of leadership in the national security sector, including service as the Under Secretary of the Navy, the Department’s second-highest-ranking civilian, responsible for the effective global business operations of the U.S. Navy and Marine Corps team. From 2017 until 2021, after his Presidential Appointment and unanimous Senate confirmation, he served as the Assistant Secretary of the Navy for Research, Development and Acquisition. Since his retirement from government, Geurts has worked extensively to improve the Nation’s defense industrial base and mentors public and private sector teams on scalability, agility, innovation, teamwork, talent development, and leadership.
“Having dedicated much of my career to serving our nation and leading teams in complex, high-stakes environments, I am deeply honored to join Kymeta as a Board Advisor,” stated James Geurts. “Their commitment to innovation, operational excellence, and leadership aligns closely with the principles I have upheld throughout my service. I look forward to contributing my experience and insights to help drive the company's continued growth and success in serving its customers, stakeholders, and communities.”
Elizabeth (Beth) Kimber is a 37-year veteran of the Central Intelligence Agency (CIA) who culminated her career as the Deputy Director of CIA for Operations (DDO) and oversaw CIA’s worldwide HUMINT operations and covert action missions. She also served as Acting Deputy Director of CIA; Assistant Director of CIA for Europe and Eurasia; Deputy Director of the National Clandestine Service, and Chief, Special Operations Department, Counterterrorism Center. She spent 18 years in the field including in assignments as Chief of Station / DNI Representative. In 2022, Kimber joined Two Six Technologies as Vice President of Intelligence Community Strategy. She also serves on the ManTech Board of Directors.
“Having spent a career supporting national security, I am honored to be a part of Kymeta’s Board of Advisors and help showcase their cutting-edge technologies and solutions to national security partners,” said Elizabeth Kimber. “Kymeta has demonstrated a steadfast commitment to innovation, integrity, and driving meaningful impact in its industry. I look forward to leveraging my experience in intelligence, risk management, and organizational leadership to support the company’s mission and help guide its continued growth and success in an ever-evolving world.”
“We are thrilled to welcome Elizabeth and James to our Board of Advisors,” said Rick Bergman, CEO and President, Kymeta. “Their voice and expertise are perfectly suited for helping Kymeta advance our vision of securing the future with innovative technology. Their extensive backgrounds in defense and space sectors are perfectly suited to help guide our business to the next phase of growth.”
About Kymeta
Kymeta revolutionizes satellite communications through Intelligent Communications Platforms (ICPs). Founded in 2012 and headquartered in Redmond, Washington, Kymeta leverages cutting-edge metamaterial-based science to engineer, manufacture and deliver resilient connectivity and enhanced situational awareness for critical, mobile applications. Backed by U.S. and international patents our electronically steered flat panel antennas enable seamless communications on-the-move. With software-defined solutions, hybrid multi-network capabilities, and edge processing, we integrate satellite and cellular networks, ensuring continuous connectivity in challenging environments. Kymeta solutions serve government, military, maritime, transport, and public safety clients worldwide, providing uninterrupted connectivity and spatial intelligence anywhere, anytime. With over 150 patents, Kymeta is shaping the future of global communications, dedicated to delivering reliable, efficient, and intelligent connectivity solutions for an increasingly mobile and connected world.
For more information, visit kymetacorp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114298718/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom